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1 Abstract
2 1. The metabolic fate and urinary excretion of 2-bromophenol, a phenolic metabolite of 
3 bromobenzene, was investigated in male Sprague Dawley rats following single intraperitoneal 
4 doses at either 0, 100 or 200 mg/kg.  
5 2. Urine was collected for seven days and samples analysed using 1H NMR spectroscopy, 
6 inductively coupled plasma (ICP)MS, and UPLC-MS. 
7 3. 1H NMR spectroscopy of the urine samples showed that, at these doses, 2-bromophenol had 
8 little effect on endogenous metabolite profiles, supporting histopathology and clinical chemistry 
9 data which showed no changes associated with the administration of 2-bromophenol at these 
10 doses. 
11 4. The use of ICP-MS Provided a means for the selective detection and quantification of 
12 bromine-containing species and showed that between 4 and 25% of the dose was excreted via the 
13 urine over the 7 days of the study for both the 100 and 200 mg doses respectively. 
14 6. The bulk of the excretion of Br-containing material had occurred by 8 hr post administration. 
15 UPLC-MS of urine revealed a number of metabolites of 2-bromophenol, with 2-bromophenol 
16 glucuronide and 2-bromophenol sulphate identified as the major species. A number of minor 
17 hydroxylated metabolites were also detected as their glucuronide, sulphate or O-methyl 
18 conjugates. There was no evidence for the production of reactive metabolites. 
19 Keywords. 2-Bromobenzene, metabolism, nephrotoxicity, metabonomics. 
20
21 Introduction
22 The compound 2-bromophenol is a metabolite of bromobenzene, a well-known nephro- and 
23 hepatotoxin, which has been used as a solvent, fire retardant and a component of motor oils. 
24 Following ingestion bromobenzene is metabolised in the liver to a range of oxidised metabolites 
25 including 2-bromophenol and 2-bromohydroxyquinone (Lau et al., 1984a). Both 2-bromophenol 
26 and 2-bromohydroxyquinone are readily transported from the liver to the kidneys, and the 
27 reaction of the latter with glutathione produces various mono-and di-substituted conjugates 
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28 (Parke and Piotrowski, 1996). The accumulation of these conjugates, in addition to the depletion 
29 of the local glutathione pool, is thought to be the cause of renal toxicity (Lau et al,1984b). In 
30 addition to 2-bromohydroxyquinone it has been suggested that 2-bromophenol is also a 
31 nephrotoxin. Thus, Bruchajzer et al (2002) observed changes in the composition of the urine of 
32 rats administered the compound, including increased protein excretion and elevated epithelial 
33 cell content, which they considered as being due to kidney damage.  However, they also 
34 observed variability in the concentrations of ‘classic markers of nephrotoxicity’ such as 
35 creatinine.  Currently, there is little information about the potential mechanism of the proposed 
36 nephrotoxicity toxicity of 2-bromophenol in the rat.
37 Here, as part of a study undertaken by the Consortium of Metabonomic Toxicology (COMET) 
38 (Lindon et al., 2005), metabolite profiling has been performed on rat urine to identify changes in 
39 endogenous metabolites and define the excretion and composition of 2-bromophenol-related 
40 material excreted via the urine following single i.p. administration of either 0, 100 or 200 mg/kg 
41 of 2-bromphenol. Urine was analysed using 1H NMR spectroscopy, bromine-detected 
42 inductively couple plasma (ICP) MS and ultra (high) performance liquid chromatography 
43 (U(H)PLC-MS) to characterise the effects of 2-bromphenol on urinary composition and 
44 determine the metabolic fate of the compound itself.
45
46 Materials and Methods
47 Solvents & chemicals
48 HPLC grade methanol (MeOH) was purchased from Fisher Scientific Leicestershire, UK). Ultra-
49 pure water (18 MΩ @ 25 ºC) was produced in-house using an ELGA (Marlow, UK) water 
50 purification system. 3-(trimethylsilyl)-[2,2,3,3,-2H4]-propionic acid (TSP) 3-[2,2,3,3-2H4] 
51 trimethylsilyl propionate sodium salt (TSP), ammonium acetate, potassium bromide, sodium 
52 dihydrogen phosphate and disodium hydrogen phosphate were purchased from Sigma-Aldrich 
53 Company, Ltd (Gillingham, UK). NMR-grade deuterium oxide (2H2O) was obtained from Goss 
54 Scientific Instruments (Nantwich, UK).
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3
55 Optima grade LC-MS water was purchased from Fluka (Leicester, UK). Acetonitrile (LC-MS 
56 grade), formic acid (LC-MS grade), ammonium acetate (LC-MS grade), leucine enkephalin 
57 acetate salt hydrate and sodium formate solution were purchased from Sigma Aldrich 
58 (Gillingham, UK).
59 Study conduct
60 Urine and serum samples were collected after the intraperitoneal (IP) administration of 2-
61 bromophenol as a single dose to male Sprague-Dawley rats. The rats (10 animals/group) were 
62 dosed with 2-bromophenol at either 100 (numbers 11-20) or 200 (number 21-30) mg/kg in corn 
63 oil (control rats (numbe s 1-10) were dosed with corn oil). Rats were housed in metabolism 
64 cages and urine was collected for metabolite profiling and clinical analysis. Urine samples were 
65 collected at 16 hours pre-dose, at time of dose and at 8, 24, 48 72, 120, 144 and 168 hours post 
66 dose, with a total of 230 samples collected. Clinical observations and body weight were recorded 
67 daily. Clinical chemistry was performed on study day 2, 24 hours after treatment (all rats); study 
68 day 3, 48 hours after treatment (group A); and on study day 8, 168 hours after treatment (group 
69 B). Five animals from each group were sacrificed on study day 3 and five were sacrificed on 
70 study day 8. Kidneys were removed and were examined histopathologically. Samples were 
71 stored at -40 °C prior to analysis. 
72 The study was subject to all relevant national regulations governing the conduct of animal 
73 studies and the specific protocols described in this paper were reviewed and approved by the local 
74 Departmental Review to ensure that they adhered to the principals of minimising animal suffering. 
75 1H NMR spectroscopy
76 Before 1H NMR spectroscopy urine samples were centrifuged at 12000G for 5 min at 4oC to 
77 remove particulates and 250 μL of sample aliquoted into 2 mL cryo-vials and diluted 1:2 with 
78 phosphate buffer. A quality control mixture containing 10 μL of each sample was also prepared. 
79 Each urine sample was centrifuged at 12000g at 4 °C for 5 min and subsequently 500 μL was 
80 transferred into 96-well plates using a Bruker (Bruker, Rheinstetten, Germany) Sample Track 
81 system and a Liquid Handler 215 preparation robot. 1H NMR spectroscopy was performed at a 
82 field strength of 14.1 T (1H 600.29 MHz) on a Bruker spectrometer using a 5 mm broadband 
83 inverse configuration probe with a z axis magnetic field-gradient capability. The spectrometer 
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84 was equipped with a Bruker Sample Jet system set to 5mm shuttle mode with a cooling rack of 
85 refrigerated tubes at 6 °C and controlled via a Bruker Avance III console. The 1H NMR spectra 
86 of the urine were measured using one-dimensional (1D) nuclear Overhauser enhancement 
87 spectroscopy (NOESY)-presat (noesypr1d) pulse sequence (Stonehouse and Keeler, 1995). The 
88 data were acquired using Topspin 3.2 and run under automation by IconNMR. 
89 1H NMR Spectral Data Analysis
90 After phasing to correct for first and zero-order errors, and baseline correction to account for 
91 distortions of the base values, the 1H NMR spectral data were imported to MATLAB R2012b 
92 (Natick, Massachusetts, U.S.A.) using the Metaspectra program script, using a resolution of 
93 0.00055. The data were then aligned using Recursive Segment-Wise Peak Alignment (RSPA) 
94 (Veselkov et al., 2008) and normalised by Probabilistic Quotient to account for, and exclude, 
95 systematic sources of bias within samples which were not due to biological processes or 
96 environment. Statistical Recouping of Variables (SRV) (Blaise et al., 2009) was then used for 
97 peak detection, and the integrated dataset was exported to SIMCA-P+ 13.0.2 software for 
98 multivariate analysis.
99 ICP-MS-based Total Bromine Analysis
100 The determination of total bromine in the samples was performed by flow injection analysis 
101 (FIA) with direct infusion of samples into the ICP-MS at 0.5 mL/min using 5 µL of 
102 sample/standard. For the purposes of quantification aqueous calibration standards were produced 
103 using potassium bromide over the concentration range 5 to 25 µg/mL using ultra-pure water. 
104 Samples were infused directly into a NexION 300D ICP-MS (PerkinElmer SCIEX, Shelton, CT 
105 USA) using a Waters Alliance 2695 HPLC system (Waters Corporation, Milford, MA) with the 
106 samples maintained at 4⁰ C within the sample compartment of the autosampler. For 
107 determination of total bromine both calibration standards and urine samples were injected into a 
108 flowing stream of a 90:10 v/v mixture of 0.1 % (v/v) nitric acid in methanol (prepared using the 
109 HPLC systems solvent mixing capability). The analysis time for the FIA was 2 minutes/sample. 
110 The concentration of bromine was determined operating the ICP-MS in standard mode (Table 
111 1). A cooled spray chamber was used to reduce the solvent loading into the plasma. Oxygen was 
112 introduced into the sample stream to reduce the build-up of carbon on the sampler cone.
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113 ICP-MS Data Processing/Analysis
114 All data was collected using NexION 1.5 software (PerkinElmer SCIEX, Shelton, CT USA), 
115 peak area integration was carried out using Analyst 1.4.2 (AB Sciex UK Ltd, Cheshire UK). 
116 Statistical analysis was carried out using Microsoft Excel 2010.
117 U(H)PLC-MS Sample Analysis 
118 A 150 µL aliquot of urine was mixed with 300 µL water to dilute the salt concentration before 
119 protein removal via precipitation with acetonitrile (1:2 v/v). These samples were vortexed and 
120 left at -20 °C overnight, then centrifuged for 5 min at 12 000 g at 4 °C before 50 µL of sample 
121 was taken and added to 150 µL water in 350 µL 96-well plates (Waters Corporation, Milford, 
122 USA) and were stored at -20°C until analysis. Prior to analysis the sample order was randomised 
123 using the Microsoft Excel random number generator function. A pooled quality control (QC) 
124 sample was prepared (Gika et al. 2008) by combining 100 µL of each sample and diluting 1:4. 
125 Immediately before analysis the plates were centrifuged at 1700 g and then placed into the 
126 autosampler at 4 °C. Reversed-phase gradient liquid chromatography was performed on an 
127 Acquity UPLC system (Waters Ltd, Elstree, UK) coupled to a Synapt G2 triple quadrupole dual 
128 time-of-flight mass spectrometer (Waters MS technologies, Ltd., Manchester). UPLC-MS was 
129 performed by injecting 2 µL of sample onto a Waters HSS T3 1.8 µm, 2.1 x 100 mm UPLC 
130 column, maintained at 40 °C, at a flow rate of performed at 0.5 mL/min. Linear gradient elution 
131 was performed using mobile phases composed of 0.1 % formic acid in water (solvent A) and 0.1 
132 % formic acid in acetonitrile (solvent B).  The starting composition was 1 % B, held for 1.0 min, 
133 increasing to 15 % at 3.0 min, 50 % at 6.0 min, 95 % at 9.0 min, returning to 1 % B at 10 min, 
134 and followed by a 2 min re-equilibration step prior to the next injection (total cycle time 12 min).  
135 Mass spectrometry was performed with electrospray ionisation operated in both positive (ESI+) 
136 and negative ion modes (ESI-) The instrument was operated in sensitivity mode and set to 
137 acquire data over the m/z range 50 – 1200 with a scan time of 0.1 s. All mass spectral data were 
138 collected in centroid mode using the MSe data acquisition function. For mass accuracy, leucine 
139 encephalin (MW = 555.62) was used as a lock mass at a concentration of 200 pg/uL (in 1:1 v/v 
140 CH3CN:H2O, 0.1 % formic acid) infused at a flow rate of 20 µL/min via a lock spray interface. 
141 The data were collected using MassLynx V 4.1 software (Waters Corporation, Milford, USA).
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142 UPLC-MS Data Analysis
143 Each UPLC-MS data set was pre-processed using Transomics (Non Linear Dynamics, UK). The 
144 ion intensities for each peak detected were then normalised, within each sample, to the median 
145 peak intensity in that sample. The resulting peak marker tables, comprising m/z, RT and 
146 normalised intensity values for each variable in every sample, were exported to SIMCA-P+ 
147 13.0.2 software (Umetrics, Umea, Sweden) for multivariate analysis. Bromine-containing 
148 metabolites were detected using the specific bromine isotope pattern.
149
150 Results and Discussion
151 Clinical Pathology
152 None of the animals in the study exhibited any major adverse clinical signs attributable to 
153 treatment with 2-bromophenol although weight loss was seen in all groups, particularly animals 
154 in the high dose group, during the first 24 hours following administration. Recovery from weight 
155 loss occurred in all groups from Day 2 although this was at a slightly lower rate for the high dose 
156 group in comparison with the control and low dose animals. By Day 8, body weights were 
157 similar for all three groups. The high dose group showed mild clinical signs, including transient 
158 tremors, slight laboured respiration and inactivity; however these effects were minor and the 
159 animals had recovered by days 2-3 post dose. 
160 As the administration of bromophenol has previously been associated with nephrotoxicity, 
161 characterised by necrotic damage to the proximal tubule cells, clinical chemistry and 
162 histopathology of the kidneys were performed. It was expected that the high dose would cause 
163 changes in the kidney but no mortality. 
164 Urinalysis showed statistically significant decreases in urinary osmolality, creatinine, potassium 
165 and glucose for the high dose animals between 0 and 8 hours after dosing on Day 1. However, 
166 there was no consistent pattern of variation in organ weight data to indicate an effect of treatment 
167 with 2-bromophenol and no macroscopic changes that could be attributed to the administration 
168 with the compound were noted at either 48 or 168 hours after dosing. Overall the clinical 
169 chemistry of the urine showed no trends and all animals were within the normal ranges for each 
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170 test. The overall results of the clinical chemistry are summarised in Table S1 in supplementary 
171 information.
172 Histopathological examination of the kidneys identified no overall effect of 2-bromophenol 
173 administration. Some general mild nephropathy was present in the kidneys of all animals (dosed 
174 and control). This not considered severe enough to cause any symptoms, although two low dose 
175 group animals did show signs of minimal localised inflammation. Two animals out of ten from 
176 the high dose group showed evidence of slight tubular regeneration, characterized by pale 
177 basophilic epithelial cells and necrotic cellular debris within the lumen of the proximal tubules 
178 but the remaining animals in this group showed no evidence of kidney damage. One control and 
179 one high dose animal showed signs of hyaline droplet formation indicative of a low level 
180 background of tubular damage in the test animals. Overall, there were no differences between the 
181 kidney tissues of any of the groups.
182 1H NMR Spectroscopic Analysis of Urine
183 The effects of 2-bromophenol administration on endogenous metabolite profiles were 
184 investigated via the multivariate statistical analysis of the 1H NMR spectral data with principal 
185 components analysis (PCA) showing a general separation of the 200 mg/kg-dosed animals from 
186 the other two groups, but very little differentiation of the 100mg/kg dose group from the controls 
187 (Supplementary data Figure S1). In the high dose group the maximal response was detected at 
188 48hrs post dose with increased amounts of hippurate (3.96/7.56/7.84 ppm, p = 7 x 10-17/3.78 x 
189 10-18/6.16 x 10-17), aminohippurate (6.87ppm, p = 1.49 x 10-17) and 3-methylhistamine (2.84 
190 ppm, p = 2.29 x 10-20) observed compared to control and low dose groups. This is illustrated in 
191 the S plot, derived from the OPLS model constructed from these data, shown in Figure 1. 
192 Hippurate is a generally ubiquitous component of urine and its utility as a potential biomarker in 
193 metabonomic studies has been reviewed by Lees et al. (2013).  In the rat the kidney represents 
194 the main route of excretion for hippurate and, if there is impaired renal function, has been seen to 
195 accumulate in the serum (Niwa, 1996) coupled with a reduction of urinary concentrations 
196 (Bairaktari et al., 2001). As a result it might be expected that, if 2-bromophenol were a 
197 nephrotoxin, urinary concentrations would fall, rather than increase as observed here. 
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8
198 Examination of the spectra from both l00 and 200 mg/kg dose groups did not reveal any 
199 significant contribution from 2-bromophenol or its metabolites at any time point.
200 ICP-MS Analysis of Urine
201 1H NMR spectroscopy had not detected any signals other than those of the normally present 
202 endogenous compounds. Therefore both bromine-detected ICP-MS (and subsequently) 
203 U(H)PLC-MS) was performed on the urine samples to determine if any 2-bromophenol-related 
204 material had been excreted in the urine and thereby confirm exposure of the kidney to it, or its 
205 metabolites. The quantitative nature of ICPMS for bromine enabled the determination of the total 
206 concentrations of 2-bromophenol-related compounds in the urine. The results of Br-detected 
207 ICP-MS clearly showed that, for both 100 and 200 mg doses, between ca. 4 and 25% of the 
208 administered bromine was excreted in the urine over the first 48 hours of dosing, the bulk of it in 
209 the first 8 hours. There was however, wide inter animal variation with, at both doses, mean 
210 excretion, up to 48 hrs post dose, of ca. 15%. The excretion of Br in the urine of the 100 mg/kg 
211 dose illustrating the time course of excretion for each animals is shown in Figure 2a and the 
212 cumulative excretion is provided in Figure 2b. Essentially similar profiles were seen for the 200 
213 mg/kg dose (data not shown).
214 U(H)PLC-MS Analysis 
215 Untargeted reversed-phase U(H)PLC-MS, in both positive and negative ESI modes, was 
216 performed on the urine samples to determine changes in endogenous metabolite profiles and 
217 characterise the metabolites of 2-bromopenol excreted in the urine. After processing with 
218 Transomics Software the extracted metabolic signatures, defined by retention time and m/z ratio, 
219 were analysed using multivariate statistics as performed on the 1H NMR spectroscopic data. The 
220 positive ESI data showed no separation by either dose group or time points on PCA, indicating 
221 minimal perturbation of the endogenous metabolites following 2-bromophenol administration, 
222 and no further analysis of these data was undertaken. In the case of the negative ESI data PCA 
223 analysis showed a good, apparently dose-dependent, separation between the control and dosed 
224 groups. Initial PCA modelling of the negative ESI dataset revealed distribution patterns within 
225 the models which indicated both dose and time-dependent effects (Figure 3). The maximal 
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9
226 “response” was seen for the high dose group, at 8 hours post dose with a diminishing effect at 24 
227 hours, after which time the metabolic profiles of the animals returned to ‘normal’.  
228
229 Furthermore, no doubt due to due to the greater sensitivity of MS analysis for some analytes, 
230 more subtle differences were detected leading to some differentiation between the low dose and 
231 control classes which were previously undetected by 1H NMR spectroscopy. Subsequent OPLS 
232 modelling (Figure 4, lower) of the 8 hour time point provided very strong models (R2 = 0.99, 
233 Q2 = 0.71). On investigation the separations was seen to be largely due to the presence of 
234 brominated metabolites of 2-bromophenol of m/z 252.93 and 348.97 respectively. Analysis of 
235 the U(H)PLC-MS data identified these discriminating ions as a direct sulfate and glucuronides of 
236 2-bromohenol respectively (Figure 4 upper). Each of these metabolites showed the distinctive 
237 1:1 isotope pattern characteristic of bromine and, due to fragmentation in the ion source, 
238 appropriate losses of 80 and 176 Da, diagnostic of the sulphate and glucuronic acid moieties 
239 respectively. An ion consistent with a 2-bromophenol glucuronide dimer (m/z 718.94), with the 
240 similar retention time to the glucuronide, was also seen. However, this was likely an artefact 
241 resulting from in source dimerization. Due to poor ionisation under these U(H)PLC-MS 
242 conditions we were unable to detect 2-bromophenol itself (either as the pure standard or in urine 
243 samples). These data are summarized in Table 2.
244 Clearly, the presence of bromine, with 79Br and 81Br isotopes present at a ratio of approximately 
245 1:1 provides a characteristic and very distinctive isotope pattern in mass spectra. We therefore 
246 searched the U(HP)LC-MS data for ions with this isotopic signature in order to highlight the 
247 presence of other metabolites of 2-bromophenol. A typical example is illustrated in Figure 5 
248 (upper) where an 0-8 hr  high dose urine sample (negative ESI data) has been used to generate an 
249 “isotopogram” by extracting all ions containing an isotopic pattern with a mass difference of 2 
250 Da at a ratio of 1:1, thereby showing only ions containing the bromine isotopic pattern. This 
251 selective trace (“bromatogram”) highlights 6 bromine-containing peaks, for which spectra are 
252 provided in Figure 5 (lower). Based on annotation using MS/MS fragmentation spectra, the first 
253 3 eluting peaks corresponded to a hydroxylated 2-bromophenol conjugated with to glucuronic 
254 acid (tentatively assigned as hydroxy 2-bromophenol glucuronide (peak 1)) and two sulphated 
255 mono-hydroxylated metabolites (peaks 2 and 3), one of which presumably corresponds to 
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10
256 hydroxy 2-bromophenol sulfate whilst the other is sulfated at the alternative hydroxyl group. The 
257 major signals detected (peaks 4 and 5) corresponded to the previously identified 2-bromophenol 
258 sulfate and glucuronide metabolites respectively. The MS/MS spectrum of the sixth peak 
259 contained the characteristic sulphate 80Da loss, plus the addition of oxygen and a methyl group 
260 leading to the tentative assignment of this compound as 2-hydroxy(3-methoxy)bromophenol 
261 sulphate (although the alternative configuration of 2-methoxy-, 3-sulfate is clearly possible). The 
262 methylation of vicinal aromatic diols by catechol-O-methyltransferase is well known (Huotari et 
263 al, 2002) and conjugation with a methyl group, which would increase the lipophilicity of the 
264 compound, is also consistent with the increased retention time of this metabolite compared to the 
265 mono-sulfate. 
266 Glutathione conjugates and related mercapturates and cysteinyl conjugates are one of the major 
267 indications of potential toxicity via reactive metabolites, and have been detected as a result of the 
268 metabolism of 2-bromohydroxyquinone. The MS data were therefore carefully searched data for 
269 any evidence of their production. However, we were unable to detect any evidence of the 
270 presence of glutathione conjugates, nor were cysteinyl or mercapturic acids detected in the urine. 
271 This suggests that 2-bromophenol, at these doses and in this strain of rat, does not produce 
272 reactive intermediates following I.P. administration.
273 To investigate any potential changes in endogenous metabolites that had been masked by the 
274 presence of the 2-bromophenol metabolites the ions for the sulphate and glucuronide conjugates 
275 were removed from the MS data which enabled the identification of hippurate, and citrate as 
276 being elevated in the 2-bromophenol dose groups
277 The absence of these metabolic markers of nephrotoxicity at either dose level, despite the clear 
278 evidence from ICP- and U(H)PLC-MS of urinary excretion, and therefore organ exposure, to 2-
279 bromophenol-related metabolites, supports the absence of kidney damage indicated by 1H NMR-
280 based metabonomic phenotyping, clinical chemistry and histopathology. The overall conclusion 
281 from this study with respect to nephrotoxicity was therefore, that, after single doses of either 100 
282 or 200 mg/kg, 2-bromophenol is not a potent nephrotoxin. 
283
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1
Table 1. Operating parameters of the PerkinElmer NexION 300D ICP-MS (*Oxygen 
introduced into the sample stream at the base of the torch).
Sample introduction
Micromist 149597 concentric nebuliser
ESI PC3 Cooled quartz cyclonic spray chamber
Quartz sample injector
Operating parameters
Plasma power 1600 W
Plasma gas (Ar) flow 18.0 L/min
Auxiliary gas (Ar) flow 1.2 L/min
Nebuliser gas (Ar) flow 1.14 L/min
DRC oxygen flow 0.6 mL/min
Oxygen flow* 0.01 L/min
Sample uptake rate 0.5 mL/min
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Table 2 Metabolites of 2-Bromophenol identified by UPLC-MS in Negative Ion ESI
Metabolite Measured 
Mass
Retention 
Time
Formula Isotopogram 
peak number
Hydroxy 2-bromophenol 
glucuronide
362.97 3.01 C12H15O9 1
Hydroxy 2-bromophenol 
sulfate
268.89 3.09 C6H7O5BrS 2
Hydroxy 2-bromophenol 
sulfate
268.89 3.39 C6H7O5BrS 3
2-bromophenol sulfate 252.90 4.47 C6H6O4BrS 4
2-bromophenol 
glucuronide
348.98 4.43 C12H14O8 5
2-bromophenol 
glucuronide dimer
718.94 4.46 -- 5
Hydroxy (3-methoxy) 2-
bromophenol sulphate
282.91 5.14 C7H8O5BrS 6
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Figure 1. An S plot derived from the OPLS model of the 1H NMR spectroscopic data, comparing high 
dose and control groups at 8 hours post dose. The data points in the bottom left quadrant of the plot, and 
therefore highly abundant in the treatment group, represent hippurate (3.96/7.56/7.84 ppm, p = 7 x 10-
17/3.78 x 10-18/6.16 x 10-17), aminohippurate (6.87 ppm, p = 1.49 x 10-17) and N-acetylhistamine (2.84 
ppm, p = 2.29 x 10-20).
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Figure 2. Determination of total bromine in rat urine by ICP-MS after I.P. administration to the 
rat administered at 100 mg/kg of 2-bromophenol by flow injection analysis. (A) Time course of 
excretion of Br and (B) Cumulative excretion of Br by individual animals.
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Figure 3. PCA scores plot of the model comparing dose groups, acquired by negative mode ionisation. 
There is good separation between the groups and the distance the samples deviate from the controls seems 
to be dose dependant.
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Figure 4.  Composite plot highlighting the two most prominent 2-bromophenol metabolites. 
Inspection of the S-plot (bottom) derived from the OPLS model comparing low dose and 
controls, the ions influencing discrimination relate to 2-bromophenol sulphate (m/z 252.9) and 2-
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bromophenol glucuronide (m/z 348.97). The chromatographic peak extraction (top) and the 
related mass spectra are also provided.
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Figure 5. Isotopogram (top) and the related mass spectra (bottom). The chromatographic peaks 
are numbered and match up to the numbered mass spectra.
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Supplementary data
The Metabolic Fate and Effects of 2-Bromophenol in Male Sprague-Dawley Rats
Table S1: Clinical Chemistry Data for 2-Bromphenol Dosing to the Rat
Treatment Dose 
mg/kg/day
Protein glucose Creatinine Potassium
8 Hours
Vehicle (corn 
oil)
0 0.23 ± 0.11 1.19 ± 0.38 8.55 ± 1.33 236 ± 38
2-Bromophenol 100 0.18 ± 0.04 1.05 ± 0.27 6.92 ± 1.43 217 ± 44
2-Bromophenol 200 0.27 ± 0.12 0.8 5± 0.27 5.21 ± 1.77 165 ± 52
Day 1
Vehicle (corn 
oil)
0 0.31 ± 0.2 1.52 ± 0.28 9.85 ± 1.23 390 ± 52
2-Bromophenol 100 0.24 ± 0.06 1.43 ± 0.35 8.18 ± 1.4 341 ± 71
2-Bromophenol 200 0.44 ± 0.13 1.45 ± 0.32 8.57 ± 2.0 317 ± 82
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For Peer Review OnlyFigure S1. The scores plots from the multivariate analysis of the NMR data. A) and B) are the scores of PCA and OPLS-DA, respectively, of the whole data set. There is trend in statistical space pushing the 200 mg/kg dose group away from the other two. This trend is highlighted 
when the 100 mg/kg dose group is removed in C) and D) (PCA and OPLS-DA, again 
respectively). The samples coloured in Yellow are QC samples and these are present consistently 
in the middle of statistical space. 
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